Growing evidence that immune system may not be source of type 1 diabetes 31 August 2022 It has long been accepted that type 1 diabetes results from the loss of immune tolerance to beta cell proteins and that susceptibility to the condition is largely due to the immune system getting out of control. Researchers at the University of Chicago have now identified a potentially critical gene tied to the progression of type 1 diabetes. The removal of this gene curbs stress signalling by the beta cells to the immune system. The study suggests that instead of the immune system being the cause of type 1 diabetes, beta cells themselves may be triggering the process. Other studies have also found that inflammatory signalling within beta cells could be a modifier of the immune response in type 1 diabetes. The University of Chicago study started on the premise that inflammatory signalling within beta cells promotes progression of autoimmunity within the islet microenvironment. To test this hypothesis, researchers identified and then deleted the proinflammatory gene encoding 12/15-lipoxygenase (Alox15) in beta cells of non-obese diabetic mice at a pre-diabetic time point when islet inflammation became evident. (Alox15 is predisposed in people with type 1 diabetes, and 12/15-Lipoxygenase is associated with inflammation in beta cells). To delete the gene, researchers treated the mice with beta cell inflammation with Nolvadex, an oestrogen receptor modulator approved to treat breast cancer. Nolvadex reduced Alox15 expression by roughly 80 per cent. Researchers subsequently identified reduced inflammation in the pockets of beta cells called islets. “When we got rid of this gene, the beta cells no longer signalled to the immune system and the immune onslaught was completely suppressed, even though we didn’t touch the immune system,” said senior author of the study, Professor Raghavendra Mirmira, a professor of medicine at the University of Chicago and director of the university’s Diabetes Translational Research Center. “That tells us that there is a complex dialogue between beta cells and immune cells, and if you intervene in that dialogue, you can prevent diabetes.” Specifically, eliminating the gene helped preserve beta cells, which produce insulin in the pancreas, and reduced the amount of infiltrating cytotoxic T cells (killer cells). That process ultimately prevented type 1 diabetes from developing. The findings are a critical piece of additional evidence to what’s been an ongoing re-evaluation of how type 1 diabetes begins.
News 24 July 2026 GLP-1 RA safety update for rare but severe eye disorders The Therapeutic Goods Administration has updated GLP-1 RA product warnings because of their potential to cause a rare but severe eye disorder. The glucagon-like peptide-1 receptor agonist... Continue Reading
Blog 22 July 2026 Living Out Loud: how Australia spoke up for National Diabetes Week 2026 From 12 to 18 July, Australians living with diabetes, alongside their carers, researchers, health professionals and clinicians, did something powerful. They... Continue Reading
News 20 July 2026 Response to media reports from 60 Minutes, The Sydney Morning Herald, and The Age regarding regulation of diabetes technologies The safety of people living with diabetes must always come first. For many Australians, technologies such as insulin pumps and continuous glucose monitors are essential tools that help prevent dangerous high and low blood glucose levels, reduce the daily burden of living with diabetes and improve long-term health outcomes. For some individuals they can be life-changing or even life-saving. Continue Reading